Organogenesis Confirmed to Start FDA License Application for ReNu

Dow Jones

2025/12/16

By Katherine Hamilton

Organogenesis received confirmation to initiate a license application with the Food and Drug Administration for its knee condition treatment ReNu.

The regenerative tissue company said Monday it plans to initiate a rolling Biologics License Application for ReNu before the end of December.

Shares gained 9% to $5.28 in after-hours trading.

The plans come after a planned Type-B meeting with the FDA, which was completed Monday, Organogenesis said.

Organogenesis has done two large Phase 3 trials of ReNu, plus a separate randomized controlled trial.

ReNu is designed to treat people with symptomatic knee osteoarthritis, a degenerative condition that causes knee pain. It affects 31.1 million Americans and is ranked among the most common causes of disability and poor quality of life, Organogenesis said.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

December 15, 2025 17:11 ET (22:11 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2591227756"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2591227756\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2591227756?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-16 06:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2591227756","market":"hk","top_or_hot":-1,"title":"Organogenesis Confirmed to Start FDA License Application for ReNu","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Organogenesis received confirmation to initiate a license application with the Food and Drug Administration for its knee condition treatment ReNu. \n</p>\n<p>\n  The regenerative tissue company said Monday it plans to initiate a rolling Biologics License Application for ReNu before the end of December. \n</p>\n<p>\n  Shares gained 9% to $5.28 in after-hours trading. \n</p>\n<p>\n  The plans come after a planned Type-B meeting with the FDA, which was completed Monday, Organogenesis said. \n</p>\n<p>\n  Organogenesis has done two large Phase 3 trials of ReNu, plus a separate randomized controlled trial. \n</p>\n<p>\n  ReNu is designed to treat people with symptomatic knee osteoarthritis, a degenerative condition that causes knee pain. It affects 31.1 million Americans and is ranked among the most common causes of disability and poor quality of life, Organogenesis said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 15, 2025 17:11 ET (22:11 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Organogenesis Confirmed to Start FDA License Application for ReNu</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrganogenesis Confirmed to Start FDA License Application for ReNu\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-12-16 06:11</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Organogenesis received confirmation to initiate a license application with the Food and Drug Administration for its knee condition treatment ReNu. \n</p>\n<p>\n  The regenerative tissue company said Monday it plans to initiate a rolling Biologics License Application for ReNu before the end of December. \n</p>\n<p>\n  Shares gained 9% to $5.28 in after-hours trading. \n</p>\n<p>\n  The plans come after a planned Type-B meeting with the FDA, which was completed Monday, Organogenesis said. \n</p>\n<p>\n  Organogenesis has done two large Phase 3 trials of ReNu, plus a separate randomized controlled trial. \n</p>\n<p>\n  ReNu is designed to treat people with symptomatic knee osteoarthritis, a degenerative condition that causes knee pain. It affects 31.1 million Americans and is ranked among the most common causes of disability and poor quality of life, Organogenesis said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 15, 2025 17:11 ET (22:11 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ORGO","symbol_name":"Organogenesis Holdings Inc","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2591227756","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2591227756","pubTimestamp":1765836660,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Organogenesis received confirmation to initiate a license application with the Food and Drug Administration for its knee condition treatment ReNu.The regenerative tissue company said Monday it plans to initiate a rolling Biologics License Application for ReNu before the end of December.Shares gained 9% to $5.28 in after-hours trading.The plans come after a planned Type-B meeting with the FDA, which was completed Monday, Organogenesis said.Organogenesis has done two large Phase 3 trials of ReNu, plus a separate randomized controlled trial.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ORGO":"Organogenesis Holdings Inc","BK4139":"生物科技"},"translate_title":"Organogenesis确认开始ReNu的FDA许可申请","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ORGO":0.9},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  Organogenesis received confirmation to initiate a license application with the Food and Drug Administration for its knee condition treatment ReNu. \n\n\n  The regenerative tissue company said Monday it plans to initiate a rolling Biologics License Application for ReNu before the end of December. \n\n\n  Shares gained 9% to $5.28 in after-hours trading. \n\n\n  The plans come after a planned Type-B meeting with the FDA, which was completed Monday, Organogenesis said. \n\n\n  Organogenesis has done two large Phase 3 trials of ReNu, plus a separate randomized controlled trial. \n\n\n  ReNu is designed to treat people with symptomatic knee osteoarthritis, a degenerative condition that causes knee pain. It affects 31.1 million Americans and is ranked among the most common causes of disability and poor quality of life, Organogenesis said. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 15, 2025 17:11 ET (22:11 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}